menu
Cancer Gene Therapy Market Opportunities And Application Analysis Report 2022
Cancer Gene Therapy Market Opportunities And Application Analysis Report 2022
Data Bridge Market Research analyses that the cancer gene therapy market which was USD 1.73 billion in 2021, would rocket up to USD 3.63 billion by 2029, and is expected to undergo a CAGR of 9.70% during the forecast period 2022 to 2029.

Cancer Gene Therapy Market Analysis Outlook

The Cancer Gene Therapy Market Research Report gives you the most current industry data and future trends. This allows you to identify products and end users that are driving revenue growth and profitability. This report provides insights into the industry and provides a list of top competitors.

Cancer Gene Therapy Market Report contains forecasts, analysis, and discussion on important industry trends, market share estimates, market size, and profiles of industry players. This report examines the potential impact of Covid-19 on the industry. It also discusses drivers, risks, and opportunities.

According to the World Health Organization, the second-leading cause of death worldwide in 2018, cancer claimed approximately 9.6 million lives. About 1 in 6 fatalities worldwide are caused by cancer. The global market for cancer gene therapy is expanding vigorously as a result of this market situation. Additionally, rising R&D investments, rising demand for DNA vaccines, improving regulatory standards regarding the quality of products used in gene therapy, and ethical acceptance of gene therapy treatments for cancer are the factors anticipated to propel growth of the global cancer gene therapy market over the course of the forecast period.

Data Bridge Market Research analyses that global cancer gene therapy market which was USD 1.73 billion in 2021, would rocket up to USD 3.63 billion by 2029, and is expected to undergo a CAGR of 9.70% during the forecast period 2022 to 2029.

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Request Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-gene-therapy-market

Competitive Landscape and Cancer Gene Therapy Market Share Analysis

The cancer gene therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cancer gene therapy market.    

Some of the major players operating in the cancer gene therapy market are:

• Biogen (U.S.)

• Sarepta Therapeutics Inc. (U.S.)

• Gilead Sciences, Inc. (U.S.)

• Amgen, Inc. (U.S.)

• Novartis AG (Switzerland)

• Orchard Therapeutics Plc (U.K.)

• Spark Therapeutics, Inc. (U.S.)

• AGC Biologics (U.S.)

• Anges, Inc. (Japan)

• Bluebird Bio, Inc. (U.S.)

• Jazz Pharmaceuticals Inc. (Ireland)

• Dynavax Technologies (U.S.)

• Human Stem Cells Institute (Russia)

• Sibiono (China)

• Shanghai Sunway Biotech Co., Ltd. (China)

• Uniqure N.V. (Netherlands)

• Gensight Biologics (France)

• Celgene Corporation (U.S.)

• Cellectis (France)

 

Global Cancer Gene Therapy Market Scope

The cancer gene therapy market is segmented on the basis of therapy and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy

Oncolytic Virotherapy

Gene Induced Immunotherapy

Gene Transfer

 End User

Hospitals

Oncology Institutes

Biotechnological Companies

Clinical Research Laboratories

 

Cancer Gene Therapy Market Regional Insights

The cancer gene therapy market is analysed and market size insights and trends are provided by country, therapy and end-user as referenced above.

The countries covered in the cancer gene therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cancer gene therapy market due to the growing number of geriatric populations, well-established health-care infrastructures with specialized medical practitioners.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the increasing consumer awareness about cancer gene therapy, increasing government initiatives in propagating this treatment.  

To Gain More Insights into the Cancer Gene Therapy Market Report, Visit @ https://www.databridgemarketresearch.com/reports/global-cancer-gene-therapy-market

COVID-19 Impact on Cancer Gene Therapy Market

The development of vaccines used to treat COVID-19 is anticipated to make extensive use of gene and cell therapy technology. The treatment of coronavirus from the standpoint of RNA interference-based gene therapy offers a more direct method of battling viral genes in addition to conventional medications and vaccines, and is probably headed for a bright future.

Recent Development

·        In June 2021, Eisai and Bristol Myers Squibb reached an agreement to work together on the creation and marketing of MORAb-202, Eisai's ADC for advanced solid tumours.

·        In June 2021, EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for advanced solid malignancies, was created through a partnership between GSK and iTeos Therapeutics.

Table of Contents

·        Report Overview

·        Market Analysis by Types

·        Product Application Market

·        Manufacturers Profiles/Analysis

·        Market Performance for Manufacturers

·        Regions Market Performance for Manufacturers

·        Global COVID-19 Impact on Artificial Discs Market Performance (Sales Point)

·        Development Trend for Regions

·        Upstream Source, Technology and Cost

·        Channel Analysis              

·        Consumer Analysis

·        Artificial Discs Market Forecast

·        Conclusion

View Detailed Table of Content@ https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-gene-therapy-market

About Data Bridge Market Research:      

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:                                                                   

Data Bridge Market Research                                        

US: +1 888 387 2818       

UK: +44 208 089 1725                              

Hong Kong: +852 8192 7475

 

E-mail: corporatsesales@databridgemarketresearch.com